Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

Dow Jones

Apr 29, 2025

By Rob Curran

Shares of online pharmacy Hims & Hers surged after it struck a deal with Danish obesity drug maker Novo Nordisk to sell its Wegovy drug in the U.S.

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week, the company said.

Shares of Hims & Hers soared 30% to $36.94 premarket, but remain below February peaks. Novo Nordisk rose 4% to $65.10.

Glucagon-like Peptide receptor agonists, also known as GLP-1 drugs, are a blockbuster category of drugs that some industry analysts say will eventually be one of the top-selling kinds of pharmaceuticals ever. The GLP-1 products, including Novo Nordisk's Wegovy and Ozempic, have shown efficacy in the treatment of diabetes and in weight reduction, among other applications. Hims & Hers had previously sold compound-pharmacy versions of the drugs under a special arrangement due to shortages.

Medical professionals have raised concerns about the ease of drug access with online pharmacies, and about potential risks associated with use of GLP-1s.

Shares of Eli Lilly, which makes a Wegovy rival called Mounjaro, ticked down.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

April 29, 2025 08:39 ET (12:39 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531445735"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531445735\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531445735?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531445735","market":"other","top_or_hot":-1,"title":"Hims & Hers Rallies After Novo Nordisk Deal on Wegovy","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of online pharmacy Hims &amp; Hers surged after it struck a deal with Danish obesity drug maker Novo Nordisk to sell its Wegovy drug in the U.S. \n</p>\n<p>\n  In a joint venture with Novo Nordisk, Hims &amp; Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week, the company said. \n</p>\n<p>\n  Shares of Hims &amp; Hers soared 30% to $36.94 premarket, but remain below February peaks. Novo Nordisk rose 4% to $65.10. \n</p>\n<p>\n  Glucagon-like Peptide receptor agonists, also known as GLP-1 drugs, are a blockbuster category of drugs that some industry analysts say will eventually be one of the top-selling kinds of pharmaceuticals ever. The GLP-1 products, including Novo Nordisk's Wegovy and Ozempic, have shown efficacy in the treatment of diabetes and in weight reduction, among other applications. Hims &amp; Hers had previously sold compound-pharmacy versions of the drugs under a special arrangement due to shortages. \n</p>\n<p>\n  Medical professionals have raised concerns about the ease of drug access with online pharmacies, and about potential risks associated with use of GLP-1s. \n</p>\n<p>\n  Shares of Eli Lilly, which makes a Wegovy rival called Mounjaro, ticked down. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2025 08:39 ET (12:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Rallies After Novo Nordisk Deal on Wegovy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Rallies After Novo Nordisk Deal on Wegovy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-29 20:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of online pharmacy Hims &amp; Hers surged after it struck a deal with Danish obesity drug maker Novo Nordisk to sell its Wegovy drug in the U.S. \n</p>\n<p>\n  In a joint venture with Novo Nordisk, Hims &amp; Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week, the company said. \n</p>\n<p>\n  Shares of Hims &amp; Hers soared 30% to $36.94 premarket, but remain below February peaks. Novo Nordisk rose 4% to $65.10. \n</p>\n<p>\n  Glucagon-like Peptide receptor agonists, also known as GLP-1 drugs, are a blockbuster category of drugs that some industry analysts say will eventually be one of the top-selling kinds of pharmaceuticals ever. The GLP-1 products, including Novo Nordisk's Wegovy and Ozempic, have shown efficacy in the treatment of diabetes and in weight reduction, among other applications. Hims &amp; Hers had previously sold compound-pharmacy versions of the drugs under a special arrangement due to shortages. \n</p>\n<p>\n  Medical professionals have raised concerns about the ease of drug access with online pharmacies, and about potential risks associated with use of GLP-1s. \n</p>\n<p>\n  Shares of Eli Lilly, which makes a Wegovy rival called Mounjaro, ticked down. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2025 08:39 ET (12:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154236417.USD","symbol_name":"BGF US FLEXIBLE EQUITY \"A2\" ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2531445735","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531445735","pubTimestamp":1745930340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of online pharmacy Hims & Hers surged after it struck a deal with Danish obesity drug maker Novo Nordisk to sell its Wegovy drug in the U.S.In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week, the company said.Shares of Hims & Hers soared 30% to $36.94 premarket, but remain below February peaks. Novo Nordisk rose 4% to $65.10.Glucagon-like Peptide receptor agonists, also known as GLP-1 drugs, are a blockbuster category of drugs that some industry analysts say will eventually be one of the top-selling kinds of pharmaceuticals ever. The GLP-1 products, including Novo Nordisk's Wegovy and Ozempic, have shown efficacy in the treatment of diabetes and in weight reduction, among other applications. Hims & Hers had previously sold compound-pharmacy versions of the drugs under a special arrangement due to shortages.Medical professionals hav","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4532":"文艺复兴科技持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4599":"减肥药","BK4588":"碎股","HIMS":"Hims & Hers Health Inc.","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVO":"诺和诺德","BK4196":"保健护理服务","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念"},"translate_title":"诺和诺德与Wegovy达成交易后，Hims&Hers股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":0.9,"NVO":1},"content_text":"By Rob Curran \n\n\n \n\n\n  Shares of online pharmacy Hims & Hers surged after it struck a deal with Danish obesity drug maker Novo Nordisk to sell its Wegovy drug in the U.S. \n\n\n  In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week, the company said. \n\n\n  Shares of Hims & Hers soared 30% to $36.94 premarket, but remain below February peaks. Novo Nordisk rose 4% to $65.10. \n\n\n  Glucagon-like Peptide receptor agonists, also known as GLP-1 drugs, are a blockbuster category of drugs that some industry analysts say will eventually be one of the top-selling kinds of pharmaceuticals ever. The GLP-1 products, including Novo Nordisk's Wegovy and Ozempic, have shown efficacy in the treatment of diabetes and in weight reduction, among other applications. Hims & Hers had previously sold compound-pharmacy versions of the drugs under a special arrangement due to shortages. \n\n\n  Medical professionals have raised concerns about the ease of drug access with online pharmacies, and about potential risks associated with use of GLP-1s. \n\n\n  Shares of Eli Lilly, which makes a Wegovy rival called Mounjaro, ticked down. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2025 08:39 ET (12:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}